- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 71
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hyperphosphatemia, Anemia, Iron Deficiency, Renal Insufficiency
- Interventions
- Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy
- Drug
- Lead sponsor
- USRC Kidney Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Anchorage, Alaska • Mesa, Arizona • Pine Bluff, Arkansas + 6 more
- Conditions
- Weight Maintenance
- Interventions
- Digital Behavioral Application
- Behavioral
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Risk Behavior, Medication Adherence, HIV
- Interventions
- 3H+ (Holistic Health for HIV), HHRP+ (Holistic Health Recovery Program)
- Behavioral
- Lead sponsor
- University of Connecticut
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Total Joint Arthroplasty, Pain, Postoperative
- Interventions
- Mobile Education Delivery, Standard Verbal and Written Education
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV, AIDS, Nicotine Dependence
- Interventions
- Bupropion, Brief Counseling, High-magnitude prize contingency management, Monitored support to quit smoking, No additional treatment, Prize contingency management for abstinence, Low intensity prize contingency management
- Drug · Behavioral
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Mechanically Ventilated Patients
- Interventions
- early PT OT
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cigarette Smoking, Nicotine Dependence
- Interventions
- Coaching calls, Nicotine replacement therapy, Financial Incentives
- Behavioral · Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
- Interventions
- DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
- Biological · Drug
- Lead sponsor
- David Bartlett
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Radiation Injury, Breast Cancer
- Interventions
- Proton beam radiation therapy., X-ray based radiation therapy, Computed Tomography (CT) Scan, Pulmonary Function Test (PFT)
- Radiation · Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Jacksonville, Florida
- Conditions
- Smoking Cessation
- Interventions
- Standard Care + Financial Incentives, Standard Care
- Behavioral · Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Stimulant Use Disorders
- Interventions
- Cultually Adapted Contingency Management (CM), Basic Contingency Management (CM)
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028 – 2030
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Opioid-Related Disorders
- Interventions
- Youth Opioid Recovery Support service model
- Behavioral
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 26 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Feeding Disorders, Feeding and Eating Disorders, Avoidant/Restrictive Food Intake Disorder
- Interventions
- Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care, Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Months to 6 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Kidney Transplantation
- Interventions
- Dose adjust group (NFAT)
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hutchinson-Gilford Progeria Syndrome
- Interventions
- Progerinin, Lonafarnib
- Drug
- Lead sponsor
- PRG Science & Technology Co., Ltd.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Thalassemia, Sickle Cell Disease, Healthy Controls
- Interventions
- Hydroxyurea, Acetazolamide
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alcohol Use Disorder, Alcohol; Liver, Post Liver Transplant, Contingency Management, Alcohol Liver Disease
- Interventions
- Contingency Management
- Behavioral
- Lead sponsor
- Arpan A. Patel, MD
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Smoking Cessation
- Interventions
- Automated Mobile Contingency Management (CM), Standard Care (SC)
- Behavioral · Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 532 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Substance Abuse
- Interventions
- contingency management, Standard Care
- Behavioral · Other
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New Britain, Connecticut
- Conditions
- Asthma
- Interventions
- omalizumab, omalizumab placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years to 20 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Substance Use Disorders
- Interventions
- Motivational enhancement therapy (MET), Contingency management, Standard Aftercare Treatment
- Behavioral
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Skin Diseases, Infectious
- Interventions
- Daptomycin, Standard of Care (SOC)
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Oakland, California • Orange, California + 18 more
- Conditions
- Heart Failure, Methamphetamine Use Disorder
- Interventions
- MUD Management (contingency management +/- adjunctive MUD pharmacotherapy), HF GDMT management
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California